-
09:45:18 AM

HRMY Stock News

06/06/23 8:05 AM
Nasdaq : HRMY
clinical trial
HARMONY BIOSCIENCES ANNOUNCES POSITIVE PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PRADER-WILLI SYNDROME AT SLEEP 2023
Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the presentation of safety and efficacy data from a Phase 2 proof-of-concept study evaluating pitolisant for the...
RHEA-AI
neutral
05/25/23 8:05 AM
Nasdaq : HRMY
clinical trial
HARMONY BIOSCIENCES COMPLETES ENROLLMENT OF PHASE 3 REGISTRATIONAL INTUNE STUDY IN IDIOPATHIC HYPERSOMNIA
The INTUNE study is a double-blind, placebo-controlled, randomized withdrawal Phase 3 registrational trial in approximately 200 adult patients with IH being conducted at 58 clinical trial sites across the U.S. The primary objective is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness.
RHEA-AI
neutral
04/24/23 8:05 AM
Nasdaq : HRMY
HARMONY BIOSCIENCES ANNOUNCES JEFFREY M. DAYNO, M.D. APPOINTED PRESIDENT & CHIEF EXECUTIVE OFFICER
Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Jeffrey M. Dayno, M.D., has been appointed President and Chief Executive Officer by the Company's Board of Directors and has been elected to join as a member of the...
RHEA-AI
very positive
03/29/23 8:05 AM
Nasdaq : HRMY
clinical trial
HARMONY BIOSCIENCES ANNOUNCES ACCELERATED TIMELINE FOR PHASE 3 INTUNE STUDY IN IDIOPATHIC HYPERSOMNIA
Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced an accelerated timeline for completing its Phase 3 INTUNE study evaluating the safety and efficacy of pitolisant in adult patients with idiopathic hypersomnia.
RHEA-AI
neutral